The Leucine Rich Repeat Containing Protein 32 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Containing Protein 32 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leucine Rich Repeat Containing Protein 32 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, and Genito Urinary System which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Idiopathic Pulmonary Fibrosis, and Kidney Fibrosis. It also reviews key players involved in Leucine Rich Repeat Containing Protein 32 targeted therapeutics development with respective active and dormant or discontinued products.
The Leucine Rich Repeat Containing Protein 32 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, and Preclinical stages are 1, 3, and 2 respectively.
Leucine Rich Repeat Containing Protein 32 overview
Leucine Rich Repeat Containing Protein 32 (LRRC32), also known as Glycoprotein A Repetitions Predominant (GARP), is a cell surface protein that plays a role in immune regulation and T-cell function. LRRC32 is primarily expressed on regulatory T cells (Tregs), a subset of T cells known for their immunosuppressive functions. LRRC32/GARP has been identified as a marker for activated Tregs, and its expression is associated with enhanced suppressive activity of these cells. The protein LRRC32 contains leucine-rich repeats, structural motifs involved in protein-protein interactions. It has been shown to interact with latent transforming growth factor-beta (TGF-beta) on the surface of Tregs. This interaction is thought to contribute to the activation of TGF-beta, a cytokine with immunosuppressive properties.
For a complete picture of Leucine Rich Repeat Containing Protein 32’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
